Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Ketamine Versus Placebo for the Treatment of Anxiety in Patients With Pancreatic Cancer
NCT05086250Phase 1Completed
- Sponsor
- Cedars-Sinai Medical Center
- Start
- Oct 2022
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ketamine in anxiety disorder (2 arms), sponsored by Cedars-Sinai Medical Center. Primary endpoint: Feasibility of enrolling subjects at 2 months. Started Oct 2022; status: completed.
02
Drugs
ketamine
03
Conditions
anxiety disorder
Beyond the preview
Go deeper on NCT05086250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05086250.